AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $255.00, with a market capitalization of 449.9B. The stock trades at a price-to-earnings (P/E) ratio of 125.65 and offers a dividend yield of 2.65%.
On 2026-07-07, AbbVie(ABBV) stock traded between a low of $254.27 and a high of $260.35. Shares are currently priced at $255.00, which is +0.3% above the low and -2.1% below the high.
AbbVie(ABBV) shares are trading with a volume of 6.88M, against a daily average of 12.69M.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
ABBV News
Key Points The iShares Core High Dividend ETF has gained more than 15% this year. The ETF has benefited from its higher exposure to high-yielding energy stock...
In a regulatory filing, AbbVie (ABBV) said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acq...
AbbVie (ABBV) announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatme...
Analyst ratings
75%
of 32 ratingsMore ABBV News
...
In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata an...
JPMorgan Equity Premium Income ETF ( $JEPI ) has risen by 1.17% in the past week. It has experienced a 5-day net inflow of $208.24 million. This is due, in par...
AbbVie stock has delivered a 170.7% total return over the past five years, yet its valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic valu...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.